Option chain shows key data for ABVC BioPharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ABVC BioPharma.

ABVC BioPharma (NASDAQ:ABVC) Stock, Option Chain

ABVC BioPharma

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Tesla stock

News

Pre-Market Outlook

Markets

Movers

ABVC

AEYE

BJDX

CSLR

CSSE

ENPH

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

NUKK

PEGY

TLSA

TRSG

TSLA

WIMI

ZPTA

Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

pharma lab worker ai

Penny Stocks

ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus licensed products&#39; and clinical trial, registration, manufacturing, supply, and distribution rights.

Why ABVC BioPharma Stock Is Up Today

Small Cap

Intraday Update

Trading Ideas

ACET

AREN

ATIF

ATUS

ATXI

AVNS

FWBI

HKIT

JFBR

KROS

Kintara Therapeutics, Inc. - Common Stock

KTRA

LFMD

MBLY

MINM

MNSO

MOBX

MPLN

NEXI

NKLA

NMRD

NUZE

OMGA

PNST

RDUS

RLMD

SGLY

SMFL

XRTX

YCBD

Shares of  Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.&lt;

Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ABVC BioPharma Inc

Customers in the U.S. looking to purchase an electric vehicle can get a $7500 federal EV tax credit for several models including from Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), and more. However, President Donald Trump on Monday said that his administration would consider ending tax credits, impacting the purchase price for eligible customers.
Vehicles That Qualify: The various Tesla electric vehicles eligible for $7,500 include select trims of the Cybertruck, Model 3, Model X, and Model Y. Other brand vehicles that qualify include the Kia EV9 and selected trims of the F-150 Lightning truck.
The only Plug-in Hybrid that qualifies for the credit is the Chrysler Pacifica PHEV.
The list of vehicles that qualify for the tax credit right now is as follows:
<ul>
<li>Acura ZDX</li>
<li>Cadillac Lyriq (Luxury and Sport Models)</li>
<li>Cadillac Optiq</li>
<li>Chevrolet Blazer EV (LT, RS, and SS Models)</li>
<li>Chevrolet Equinox EV (LT and RS Models)</li>
<li>Chevrolet Silverado EV (LT Model)</li>
<li>Ford F-150 Lightning (Flash, Lariat and XLT Trims)</li>
<li>Honda Prologue</li>
<li>Jeep Wagoneer S</li>
<li>Kia EV6</li>
<li>Kia EV9</li>
<li>Tesla Cybertruck (Single Motor and Dual Motor)</li>
<li>Tesla Model 3 (Long Range AWD, Long Range RWD, Performance variants)</li>
<li>Tesla Model X (AWD Variant)</li>
<li>Tesla Model Y (Long Range AWD, Long Range RWD, Performance variants)</li>
<li>Chrysler Pacifica PHEV</li>
</ul>
Trump&#8217;s Take On EV Tax Credits: In November, Reuters reported that Donald Trump‘s transition team plans to kill the $7,500 tax credit available on EV purchases. On Monday, after his inauguration, Trump himself said his administration would consider ending EV tax credits.
&#8220;The Republicans have a very small majority in the House, which could make it hard for the party to pass legislation of any kind,&#8221; The Future Fund Managing Partner Gary Black said about a possible repeal of the tax credit on Monday. &#8220;Another wild card is Elon Musk, with $TSLA accounting for nearly half of all EVs sold in the country. With Elon Musk close to the president, it is important to know how he will seek to shape changes to the tax credit. Other auto executives have also been lobbying Mr. Trump against a repeal of the credit. Among them is Ford's executive chairman, William C. Ford Jr., who recently spoke to the president-elect.&#8221;
However, Tesla CEO Elon Musk, a close Trump ally, has previously supported scrapping of the tax credit. 
"In my view, we should end all government subsidies, including those for EVs, oil and gas," Musk said in November.
During Tesla&#8217;s second-quarter earnings in late July, Musk also said that the impact of the elimination of subsidies&nbsp;<a href="https://www.benzinga.com/news/24/07/39934750/trump-presidency-and-ira-cut-would-be-devastating-for-competitors-says-elon-musk-long-term-probably" target="_blank" rel="noreferrer noopener">would only be slight for Tesla</a>&nbsp;but devastating for its competitors. The elimination of EV subsidies would probably help Tesla in the long term, he added.
However, not all are in agreement. Tesla researcher Troy Teslike has previously said that the loss of tax credit will only make Tesla<a href="https://www.benzinga.com/24/12/42641207/researcher-says-cancelation-of-7500-ev-tax-credit-could-impact-teslas-deliveries-despite-ceo-elon-musk-claiming-otherwise" target="_blank" rel="noreferrer noopener">&nbsp;lose its market to gas cars</a>&nbsp;from luxury car brands.
Trump, on Monday also revoked a 2021 executive order signed by former President Joe Biden that sought to ensure that 50% of new vehicles sold in the U.S. by 2020 are electric.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43080738/nhtsa-opens-probe-into-about-878000-gm-gas-vehicles-days-after-closing-investigation-into-its-cruise-avs" target="_blank" rel="noreferrer noopener">NHTSA Opens Probe Into Nearly 878,000 GM Vehicles Over Engine Failure Concerns Days After Closing Investigation Into Its Cruise AVs</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration

Amcon Distributing (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DIT#AMEX">DIT</a>) reported quarterly earnings of $0.57 per share. This is a 67.98 percent decrease over earnings of $1.78 per share from the same period last year. The company reported $711.27 million in sales this quarter. This is a 10.28 percent increase over sales of $644.96 million the same period last year.

Earnings

Reported Monday, Amcon Distributing Q1 EPS $0.57 Down From $1.78 YoY, Sales $711.27M Up From $644.96M YoY

<ul>
<li>Significant portfolio expansion to include combat-proven autonomous airborne platforms in support of critical forward-looking national security mission needs</li>
<li>Expected to be immediately accretive to Revenue, Adjusted EBITDA and Free Cash Flow</li>
<li>Post-transaction, Redwire expects to have a strong balance sheet</li>
</ul>

Reported Sunday, Redwire To Acquire Edge Autonomy In $925M Deal, Transforming Into A Multi-Domain Space And Defense Leader

Collaboration will bring bespoke content and never-before-seen show integrations

Reported Sunday, BetMGM Secures Online Casino Rights For Fremantle's "Family Feud" And "The Price Is Right"

Programming Already Restored for Two Million Viewers, Including NFL Playoff Games and Local News

NXST

Reported Saturday, Nexstar And Optimum Reach Agreement To Restore Programming For Two Million Customers

<a href="https://www.globenewswire.com/Tracker?data=ZJKetO8zE3erzqRGF_P7-sCgwYhySBueJMgNqynfM3aNltyVHIqgYbS_u8Uz3Nv7SKdETdCLI16Ppo7Wvc4v8A==">NANOBIOTIX</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (<a href="https://www.globenewswire.com/Tracker?data=9AF1jPR-HWZ8jVuLKKF7MX10tUChZ_X2NGuXvAVUyFwhfw23CgjxX9aY63wN0Kdaec4QfEQsIuazNYZjxTvGX2JHp8IO-l0T8OXn7FrEKgkLxinTtGOoP8RlFCRY0HK-ieJqCKDibtD2Daq_RvrOBA==">NCT06667908</a>). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson &amp; Johnson Company, under a global license agreement.

NBTX

Nanobiotix Begins Phase 2 Trial for Innovative Cancer Treatment in Stage 3 Lung Cancer

ARBK

Argo Blockchain CEO Thomas Chippas To Exit; CFO Jim MacCallum Appointed As Interim Successor

The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/SCHW/earnings">opening bell, on Tuesday, Jan. 21, 2025.</a>
Analysts expect the Westlake, Texas-based company to report quarterly earnings at 91 cents per share, up from 68 cents per share in the year-ago period. Charles Schwab projects quarterly revenue of $5.2 billion, compared to $4.46 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 13, Charles Schwab said it expects FY24 net revenue to grow by 3.0%-3.5% versus the prior year.
Charles Schwab shares gained 1.2% to close at $76.41 on Friday&nbsp;&nbsp;&nbsp; .
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SCHW/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Wells Fargo analyst Michael Brown maintained an Equal-Weight rating and cut the price target from $90 to $89 on Jan. 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Christopher Allen maintained a Neutral rating and cut the price target from $85 to $80 on Jan. 10, 2025. This analyst has an accuracy rate of 77%.</li>
<li>JP Morgan analyst Kenneth Worthington maintained an Overweight rating and raised the price target from $87 to $93 on Jan. 7, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Piper Sandler analyst Patrick Moley maintained a Neutral rating and raised the price target from $65 to $70 on Jan. 7, 2025. This analyst has an accuracy rate of 81%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintained an Outperform rating and raised the price target from $81 to $93 on Dec. 20, 2024. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-1024x576.png" alt="" class="wp-image-741030" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43054647/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Price Target

Analyst Ratings

SCHW

Charles Schwab Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

GOEV

Reported Friday, Canoo Announces Chapter 7 Bankruptcy Filing, Ending Operations Effective Immediately

SPPL

Reported Friday, SIMPPLE Receives Nasdaq Notifications For Minimum Equity And Annual Meeting Deficiencies

Macro Economic Events

Econ #s

Economics

U.K. Unemployment Rate For November 4.4% Vs. 4.3% Est.; 4.3% Prior

U.K. Employment Change 3M/3M (MoM) For November 35K Vs. 35K Est.; 173K Prior

U.K. Claimant Count Change For December 0.7K Vs. 10.3K Est.; -25.1K (Revised) Prior

U.K. Average Earnings Index +Bonus For November 5.6% Vs. 5.6% Est.; 5.2% Prior

<ul>
<li>Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function</li>
<li>The transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicity</li>
<li>More than 800 million people have Chronic Kidney Disease (CKD), one of the world's leading causes of mortality worldwide, with associated deaths increasing over the past two decades1</li>
</ul>

VATE

Reported Friday, INNOVATE Announces FDA Approval Of MediBeacon's TGFR System For Accurate Kidney Function Testing

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares dropped 2.35% in overnight trading on Robinhood Markets on Tuesday, falling to $386.80 as cryptocurrency markets reacted to President Donald Trump&#8216;s inauguration speech that notably <a href="https://www.benzinga.com/25/01/43086698/crypto-market-plunges-after-trumps-inaugural-speech-fails-to-mention-digital-assets">omitted any mention of digital assets</a>.
What Happened: The enterprise software company, which holds over $45 billion in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), had seen its stock surge 8.04% to $396.50 on Friday amid optimism about Trump&#8217;s anticipated crypto-friendly policies. 
The company&#8217;s executive chairman Michael Saylor attended a &#8220;Crypto Ball&#8221; last Friday where he met with Trump&#8217;s incoming cabinet members, fueling speculation about <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43078515/michael-saylor-meets-trumps-cabinet-at-crypto-ball-what-does-the-bitcoin-bulls-cryptic-post-indicate">favorable cryptocurrency regulations</a>.
However, Trump&#8217;s inaugural address focused instead on traditional assets, declaring the start of a &#8220;Golden Age of America&#8221; &#8211; a reference that prompted Bitcoin critic Peter Schiff to highlight the president&#8217;s apparent preference for gold over cryptocurrency. 
See Also: <a href="https://www.benzinga.com/25/01/43088034/bitcoin-ethereum-dogecoin-retrace-from-pre-inauguration-highs-as-trumps-address-disappoints-analyst-highlights-possibility-of-btc-consolidation-in-101k-106k-range">Bitcoin, Ethereum, Dogecoin Retrace From Pre-Inauguration Highs As Trump Skips Crypto Mention: Analyst Highlights BTC Consolidation In $101K-$106K Range</a>
Why It Matters: The speech&#8217;s omission of digital assets triggered a broader <a href="https://www.benzinga.com/25/01/43088563/bitcoin-vs-gold-peter-schiff-decodes-trumps-golden-age-reference-in-inaugural-speech">crypto market decline</a>, with Bitcoin falling from $106,000 to $101,775.
The selloff comes as Trump named Mark Uyeda as acting U.S. Securities and Exchange Commission chair, replacing Gary Gensler. 
The firm has been purchasing Bitcoin for ten consecutive weeks, according to its public disclosures.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43088840/donald-and-melania-trump-memecoins-crash-after-presidential-inaugurationfirst-couples-crypto-wealth-plunges-36">Donald And Melania Trump Memecoins Crash, Erode Billions In Investors&#8217; Wealth</a></li>
</ul>
Image Via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

$BTC

MSTR

MicroStrategy Drop 2.35% On Overnight Trading After Trump's Inauguration Speech Sidelines Cryptocurrency, Bitcoin Retreats Below $102K

Uniti intends to use the net proceeds of the offering to, among other things, repay and terminate its existing ABS bridge facility and for general corporate purposes, which may include success-based capital investments and/or repayment of outstanding debt.

UNIT

Reported Friday, Uniti Group Prices $589M Fiber Securitization Notes Secured By Florida And Gulf Coast Assets With 2030 Repayment Target

EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) reported quarterly losses of $(2.80) per share. This is a 53.33 percent increase over losses of $(6.00) per share from the same period last year. The company reported $21.10 million in sales this quarter. This is a 32.53 percent increase over sales of $15.92 million the same period last year

EZGO

Reported Friday, EZGO Technologies FY EPS $(2.80) Up From $(6.00) YoY, Sales $21.10M Up From $15.92M YoY

<ul>
<li>First approval in the U.S. for Daiichi Sankyo and AstraZeneca's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy</li>
<li>Second DXd antibody drug conjugate approved in U.S. based on Daiichi Sankyo's DXd technology</li>
</ul>

DSNKY

Reported Friday, FDA Approves Daiichi Sankyo And AstraZeneca's DATROWAY AS A New Treatment Option For HR Positive, HER2 Negative Breast Cancer In The U.S.

Billionaire investor and television personality&nbsp;Mark Cuban&nbsp;threw a subtle dig at President Donald Trump&#8217;s newly launched meme coin on Monday, saying that he too can consider launching a similar project but with a major twist.
What Happened: In a series of tweets, Cuban proposed issuing a meme coin,<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43078040/trump-coin-tanks-36-even-as-melania-trump-launches-her-own-token-top-analyst-says-his-short-is-going-very-very-well"> similar</a> to the Official Trump (TRUMP) token, with a 20% supply open for public trading and following the same unlock schedule. 
The difference? All&nbsp;revenue from the sale of&nbsp;these coins would go directly to the U.S. Treasury. For transparency, Cuban proposed making the details of wallet addresses public.
&#8220;If you want to gamble,&nbsp;gamble. But at least use&nbsp;it to make a dent&nbsp;in the U.S. debt,&#8221; the "Shark" said.
U.S. debt has <a href="https://www.benzinga.com/markets/25/01/43075983/us-dollar-treasury-etfs-oil-prices-chinas-economy-and-ray-dalios-us-debt-warning-this-week-in-economics">ballooned past $36 trillion</a>, with interest payments exceeding $892 billion in fiscal year 2024. The gravity of the issue could be gauged by the fact that the U.S. accounts for 34.6% of global debt.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If meme coins are the way, maybe I'll issue one. With a twist. Same terms as <a href="https://twitter.com/search?q=%24TRUMP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TRUMP</a> . 20% float. Same release schedule. One difference. All the revenue from the sale of the coins go to the US Treasury. The wallet address will be published so everyone can track it. If…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1881445569727758392?ref_src=twsrc%5Etfw">January 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The idea was countered by a widely followed X user going by the pseudonym artchick.eth, who argued that issued by celebrities will not benefit holders in the long run.
Cuban agreed with these assertions, stating that only a few meme coin projects like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) have been successful, thanks to community engagement.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We agree. It's why Doge, Shibu Inu and only a few others have worked. It's about the community long term. I'm not saying buyers won't get rekt. I said it was gambling. It's a game of musical chairs. No promises. No pumps by me. Just complete transparency
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1881449813042246128?ref_src=twsrc%5Etfw">January 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/01/43087038/trump-names-uyeda-acting-sec-chair-as-crypto-regulations-get-set-for-a-makeover">Trump Names Uyeda Acting SEC Chair, Regulators Get Ready For Crypto Makeover</a>
Why It Matters: Cuban&#8217;s statements follow the hysteria sparked by Trump&#8217;s memecoin project, which soared to billions of dollars in market price over the weekend, <a href="https://www.benzinga.com/25/01/43088840/donald-and-melania-trump-memecoins-crash-after-presidential-inaugurationfirst-couples-crypto-wealth-plunges-36">only to plummet </a>on the day of the presidential inauguration.
The Trump memecoin was followed by an official memecoin from First Lady Melania Trump, which similarly crashed after the initial frenzy.
Cuban has previously stated that <a href="https://www.benzinga.com/general/entertainment/24/12/42545829/mark-cuban-expresses-sympathy-for-hawk-tuah-girl-amid-meme-coin-controversy-wasnt-something-she-fully-understood">he is&nbsp;not a fan of memecoins</a>, calling them a "game of musical chairs with&nbsp;money."
Price Action: At the time of writing, TRUMP was exchanging hands at $34.50, crashing 42.43% in the last 24 hours, <a href="https://coinmarketcap.com/currencies/official-trump/">according </a>to CoinMarketCap. MELANIA token tanked 62.88% in the last 24 hours.
Image via Flickr
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43086309/trumps-doge-committee-faces-lawsuit-over-alleged-federal-advisory-violations-and-lack-of-transparency">Trump&#8217;s DOGE Committee Faces Lawsuits Over Alleged Federal Advisory Violations, Lack Of Transparency</a></li>
</ul>

Politics

$DOGE

$SHIB

Mark Cuban Proposes TRUMP-Like Crypto To Lessen US Debt — 'Shark' Counts Dogecoin, Shiba Inu Among  Successful Memecoin Projects

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ABVC BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abvc-stock-quote/">ABVC</a>) just reported results for the second quarter of 2024.<ul><li>ABVC BioPharma reported earnings per share of -9 cents.</li><li>The company reported revenue of $117,142.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/abvc-stock-earnings-abvc-biopharma-for-q2-of-2024/">ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024

ABVC BioPharma GAAP EPS of -$0.09

An announcement from ABVC BioPharma, Inc. (ABVC) is now available. ABVC BioPharma, Inc. has recently updated its corporate presentation, details of...

ABVC BioPharma Releases Corporate Presentation Update

ABVC BioPharma (ABVC) announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has receiv...

ABVC BioPharma receives $50,000 in incremental licensing fees

ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb

Reports Q3 revenue $389,276 vs $15,884 last year. Improved Cash Position: The Company's cash and cash equivalents reached $137,344 as of September ...

ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year

ABVC BioPharma GAAP EPS of -$0.02, revenue of $0.38M

ABVC BioPharma (ABVC) announced the receipt of a $200,000 cash payment from OncoX BioPharma as part of its strategic licensing agreement for certai...

ABVC BioPharma receives $200,000 cash payment from OncoX

ABVC BioPharma gets $200K in cash from OncoX BioPharma

ABVC BioPharma (ABVC) announced in response to the discontinuation of Prozac due to increasing concerns around side effects, ABVC believes its ABV-...

ABVC BioPharma believes ABV-1504 can fill void in market after Prozac

Health Care

Press Releases

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Opinion

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

ABVC BioPharma's CEO Discusses New Drug Development and AI Integration

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

General

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

Comments

ABVC BioPharma

ABVC BioPharma (ABVC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga